Lymphoma is broadly divided into two main categories, Hodgkin lymphoma and non-Hodgkin lymphoma, but these split further into four major types: classical Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, and T-cell non-Hodgkin lymphoma. Together, these four groups account for the full spectrum of lymphoma diagnoses, though each one contains additional subtypes that behave quite differently from one another.
Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (CHL) is the most common form of Hodgkin lymphoma, making up roughly 90% of all Hodgkin cases. It develops from B cells that originated in the germinal centers of lymph nodes, the areas where immune cells normally mature and learn to fight infections. What makes CHL distinctive is the presence of abnormally large cancer cells called Reed-Sternberg cells, which are scattered among a dense background of normal immune cells. In fact, the actual tumor cells make up only a small fraction of the mass, while the rest consists of the body’s own immune response surrounding them.
CHL itself has four recognized subtypes: lymphocyte-rich, mixed cellularity, lymphocyte-depleted, and a general “not otherwise specified” category. These subtypes differ in how the mix of normal and cancerous cells looks under a microscope, and they can influence prognosis and treatment decisions. Despite these variations, classical Hodgkin lymphoma generally responds well to treatment. Most patients are diagnosed between ages 15 and 35 or after age 55, and swollen, painless lymph nodes in the neck or chest are often the first sign.
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
This type accounts for the remaining roughly 10% of Hodgkin lymphoma cases. It behaves quite differently from the classical form. The cancer cells, sometimes called “popcorn cells” because of their unusual shape, retain more of their original B-cell identity. Under a microscope, the cells still express the B-cell marker CD20, which classical Hodgkin cells typically lose. This distinction matters because it opens the door to different treatment options.
Nodular lymphocyte-predominant Hodgkin lymphoma tends to grow slowly, is more often caught at an early stage, and carries an excellent long-term outlook. It most commonly appears as a single swollen lymph node in the neck, armpit, or groin. Because of its indolent nature, some patients with very limited disease may be monitored closely rather than treated immediately.
B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) is far more common than Hodgkin lymphoma, with over 553,000 new cases diagnosed worldwide each year. About 90% of all NHL cases are B-cell lymphomas, making this the largest single category of lymphoma by a wide margin. Roughly 85,600 Americans receive an NHL diagnosis annually, and the vast majority fall into this group.
Within B-cell NHL, two subtypes dominate. Diffuse large B-cell lymphoma (DLBCL) is the single most common lymphoma of any kind, accounting for about 30% of all NHL diagnoses. It is an aggressive cancer, meaning it grows quickly, but it also responds well to treatment in many cases. Follicular lymphoma is the second most common, representing about 20% of NHL cases. Unlike DLBCL, follicular lymphoma is indolent, growing slowly over months or years. Some people with follicular lymphoma have no symptoms at diagnosis and may not need treatment right away.
Other notable B-cell subtypes include mantle cell lymphoma, Burkitt lymphoma, and marginal zone lymphoma. Each has its own growth rate, typical age of onset, and treatment approach. What they share is that they all arise from B cells at different stages of development, and doctors can tell them apart by examining specific protein markers on the cell surface. The overall five-year survival rate for non-Hodgkin lymphoma sits at 74.3%, though this varies significantly depending on the specific subtype and how far it has spread at diagnosis.
T-Cell Non-Hodgkin Lymphoma
T-cell lymphomas are considerably rarer, making up about 10% of all non-Hodgkin lymphoma cases in the United States. They arise from T cells or, in some cases, closely related natural killer (NK) cells. These lymphomas tend to be more aggressive and harder to treat than their B-cell counterparts, though outcomes vary by subtype.
The most common form is peripheral T-cell lymphoma not otherwise specified, which accounts for about 6% of all lymphomas. Angioimmunoblastic T-cell lymphoma makes up roughly 4%, and anaplastic large cell lymphoma about 2%. T-cell lymphomas can also affect the skin, as in cutaneous T-cell lymphoma (including mycosis fungoides), which behaves very differently from the types that start in lymph nodes. Some skin-based T-cell lymphomas progress slowly over many years, while those arising in the lymph nodes or organs are often fast-growing.
How Symptoms Overlap Across Types
Despite their biological differences, most lymphomas produce a similar set of initial symptoms. Swollen lymph nodes that are painless and persist for weeks are the most common first sign, typically in the neck, armpits, or groin. Many people also experience drenching night sweats, persistent fatigue, and unexplained weight loss. Doctors refer to the combination of fevers, night sweats, and weight loss as “B symptoms,” and their presence can influence how the lymphoma is staged and treated.
Because these symptoms overlap so heavily, the type of lymphoma cannot be determined from symptoms alone. A biopsy is required. Doctors examine the tissue under a microscope and use protein markers on the cell surface to identify whether the cancer cells are B cells, T cells, or Reed-Sternberg cells. Flow cytometry and immunohistochemistry staining are the primary tools for this. Genetic testing can further pinpoint the exact subtype.
How Lymphoma Is Staged
All four types of lymphoma use the same staging system, called the Lugano classification. It assigns a stage from I to IV based on how widely the cancer has spread:
- Stage I: Cancer is in one lymph node region or one organ outside the lymph system.
- Stage II: Cancer is in two or more lymph node regions on the same side of the diaphragm (the muscle separating the chest from the abdomen).
- Stage III: Cancer is in lymph node regions on both sides of the diaphragm, or in nodes above the diaphragm plus the spleen.
- Stage IV: Cancer has spread beyond the lymph system into organs like the bone marrow, liver, or lungs.
Staging is typically done with PET-CT scans for aggressive lymphomas that show high metabolic activity, and with standard CT scans for slower-growing types. The stage at diagnosis is one of the strongest predictors of outcome, but the specific subtype matters just as much. An aggressive lymphoma caught at stage II may actually have a better prognosis than an indolent lymphoma that has transformed into a faster-growing form.
Indolent vs. Aggressive: Why It Matters
Across all four types, one of the most important distinctions is whether a lymphoma is indolent (slow-growing) or aggressive (fast-growing). This classification shapes the entire treatment approach. Aggressive lymphomas like DLBCL or peripheral T-cell lymphoma need treatment quickly but are often curable. Indolent lymphomas like follicular lymphoma may not need immediate treatment, but they are harder to cure completely and tend to recur over time.
Some indolent lymphomas can transform into aggressive forms, which is why ongoing monitoring matters even when active treatment is deferred. If a previously slow-growing lymphoma suddenly causes new symptoms, rapid weight loss, or fast-growing nodes, doctors may biopsy again to check for transformation. This shift in behavior can change both the diagnosis and the treatment plan entirely.